The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes
Despite significant advances, the eradication of cancer remains a clinical challenge which justifies the urgent exploration of additional therapeutic strategies such as immunotherapies. Human peripheral Vγ9Vδ2 T cells represent an attractive candidate subset for designing safe, feasible and effectiv...
Main Authors: | Chirine Rafia, Clément Loizeau, Ophélie Renoult, Christelle Harly, Claire Pecqueur, Noémie Joalland, Emmanuel Scotet |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1066336/full |
Similar Items
-
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
by: Laura A. Ridgley, et al.
Published: (2023-01-01) -
Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance
by: Oliver Nussbaumer, et al.
Published: (2020-03-01) -
The Proportion of Vδ1T Cells in Peripheral Blood Correlated with Prognosis of Sepsis
by: Fawei Yuan, et al.
Published: (2022-09-01) -
Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
by: Claudia Giannotta, et al.
Published: (2023-04-01) -
B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma
by: Yi Wang, et al.
Published: (2023-09-01)